Sarah Clifford

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Ezra Y. Rosen, Melissa L. Johnson, Sarah Clifford et al. · Clinical Cancer Research · 2020 · 121 citations · Full text

Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i> -Mutant and <i>RET</i> Fusion-Positive Lung Cancers

Julia Rotow, Jyoti D. Patel, Matthew P. Hanley et al. · Clinical Cancer Research · 2023 · 40 citations · Full text

Phase IB Study of Osimertinib in Combination with Navitoclax in <i>EGFR</i>-mutant NSCLC Following Resistance to Initial <i>EGFR</i> Therapy (ETCTN 9903)

Erin M. Bertino, Ryan D. Gentzler, Sarah Clifford et al. · Clinical Cancer Research · 2020 · 39 citations · Full text

Identification of a RAS-activating <i>TMEM87A–RASGRF1</i> Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer

Alissa J. Cooper, Yoshihisa Kobayashi, Dewey Kim et al. · Clinical Cancer Research · 2020 · 25 citations · Full text

FP14.07 Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions

Julia Rotow, Jyoti D. Patel, Matthew P. Hanley et al. · Journal of Thoracic Oncology · 2021 · 25 citations · Full text

Fp14.07 Combination Osimertinib, Acquired Ret Fusions, Medicine +7